

**Nombre:** Luis Alejandro Pérez de Llano.

-Edad 57 años. DNI: 33266903W

-Licenciado en Medicina por la Facultad de Santiago de Compostela (1989)

-Neumólogo (residencia en el H Marqués de Valdecilla, 1995).

-Doctor en Medicina y Cirugía por la Universidad de Cantabria (2006).

-Máster en Dirección de Unidades de Gestión Clínica por la UCAM (2014).

-Profesor Asociado de la Universidad de Santiago de Compostela.

**Cargos:**

-Jefe de Servicio de Neumología del HULA desde el año 2005. Lugo.

-Patrono de la Fundación Ramón Domínguez.

-Presidente del Comité de Investigación del Hospital Lucus Augusti.

-Director del PII de Asma de SEPAR desde Junio del 2018 hasta el año 2023.

- Director del Comité de Formación Continuada de la Sociedad Española de Patología Respiratoria (SEPAR) los años 2011-2014.

**Áreas de interés:**

-Responsabilidad asistencial e investigación clínica en asma.

-Investigación clínica en ventilación no invasiva.

**Estudios activos en los que participo como promotor:**

-Estudio sobre la prevalencia de un patrón inflamatorio "T2-alto" definido por eosinofilia en esputo con número normal de eosinófilos en sangre en una población de pacientes con asma grave no controlada en Galicia. (Estudio ESGARRAMOS).

- Aumento en la dosis del corticoide inhalado vs triple terapia en pacientes con asma T2-alta que no alcanzan el control con dosis medias de combinación corticoide inhalado/beta-agonistas de larga duración: estudio en vida real. Estudio TRICORDA (Triple vs Inhalados CORTicoides a Dosis Altas). Ensayo clínico pendiente de valoración por el ISCIII.

-Title: T2 inflammatory response in asthma and COPD: differences and similarities. Estudio de transcriptómica financiado con una "Innovation Grant" de Sanofi (150.000 E).

-Impacto del tratamiento del asma con corticoides inhalados en la función del eje hipotálamo-hipófiso-suprarrenal. Pendiente de enviar contestación al CEIC.

-Estudio REMOTE: Impact of response to monoclonal antibodies on FEV1 decline in severe asthma patients.

#### Últimas publicaciones:

1. Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S, Golpe R, Méndez Marote L, Castro-Castro J, González Quintela A. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. PLoS One. 2015; 10(2): e0117808.
2. Cisneros Serrano C, Melero Moreno C, Almonacid Sánchez C, Perpiñá Tordera M, Picado Valles C, Martínez Moragón E, Pérez de Llano L, Soto Campos JG, Urrutia Landa I, García Hernández G. Guidelines for Severe Uncontrolled Asthma. Arch Bronconeumol. 2015; 51(5): 235-246.
3. Pérez de Llano LA, García Rivero JL, Pallares A, Mengual N, Golpe R. Cortico-dependent Asthma: Our Clinical Experience. Arch Bronconeumol. 2015 Apr 21.
4. Golpe R, Mengual-Macénlle N, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O, Pérez-de-Llano LA. Prognostic Indices and Mortality Prediction in COPD Caused by Biomass Smoke Exposure. Lung. 2015 Apr 30.
5. Plaza V, Fernández-Rodríguez C, Melero C, Cosío BG, Entrenas LM, Pérez de Llano L, Gutiérrez-Pereyra F, Tarragona E, Palomino R, López-Viña A. [Validation of the 'Test of the Adherence to Inhalers' \(TAI\) for Asthma and COPD Patients.](#) J Aerosol Med Pulm Drug Deliv. 2015 Jul 31.
6. Miravittles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, Cisneros C, de-Torres JP, Entrenas LM, Esteban C, García-Sidro P, Cosio BG, Huerta A, Iriberry M, Izquierdo JL, López-Viña A, López-Campos JL, Martínez-Moragón E, Pérez de Llano L, Perpiñá M, Ros JA, Serrano J, Soler-Cataluña JJ, Torrego A,

- Urrutia I, Plaza V. [What pulmonologists think about the asthma-COPD overlap syndrome](#). *Int J Chron Obstruct Pulmon Dis*. 2015; 10: 1321-30.
7. Pérez de Llano LA, Villoro R, Merino M, Gómez Neira MD, Muñiz C, Hidalgo Á. Cost Effectiveness of Outpatient Asthma Clinics. *Arch Bronconeumol*. 2015 Nov 5. pii: S0300-2896(15)00376-2.
  8. Quality indicators of asthma care derived from the Spanish guideline for asthma management (GEMA 4.0): A multidisciplinary team report. Quirce S, Delgado J, Entrenas JL, Grande M, Llorente C, López Viña A, Martínez Moragón E, Mascarós E, Molina J, Olaguibel JM, Pérez de Llano LA, Perpiñá Tordera M, Quintano JA, Rodríguez M, Román-Rodríguez M, Sastre J, Trigueros JA, Valero AL, Zoni AC, Plaza V; ASMAFORUM II Group. *J Investig Allergol Clin Immunol*. 2016 Nov 11:0. doi: 10.18176/jiaci.0121
  9. Excessive variability in the performance and interpretation of the metacholine bronchial challenge test. Martínez Moragón E, Pérez de Llano L, Perpiñá M. *Arch Bronconeumol*. 2016; 52(11): 574.
  10. Clinical significance of the oral corticosteroid reversibility test in asthma with fixed airflow obstruction. Riaño Pérez A, Pérez de Llano LA, Mengual N, Golpe R. *Arch Bronconeumol*. 2017; 53(1) :40.
  11. Blood Pressure Profile and Hypertensive Organ Damage in COPD Patients and Matched Controls. The RETAPOC Study. Golpe R, Mateos-Colino A, Testa-Fernández A, Pena-Seijo M, Rodríguez-Enríquez M, González-Juanatey C, Martín-Vázquez FJ, Pose-Reino A, Domínguez-Pin N, Garnacho-Gayarre N, Pérez-de-Llano LA. *PLoS One*. 2016; 11(6): e0157932.
  12. Asthma, Chronic Obstructive Pulmonary Disease and Other Combinations. Pérez de Llano LA, Cosío BG. *Arch Bronconeumol*. 2016; 52(10): 499-500.
  13. Cost-effectiveness of Continuous Positive Airway Pressure Treatment in Moderate-Severe Obstructive Sleep Apnea Syndrome. Català R, Villoro R, Merino M, Sangenís S, Colomé L, Hernández Flix S, Pérez de Llano LA. *Arch Bronconeumol*. 2016; 52(9): 461-9.
  14. Pérez de Llano LA, Cosío BG. Asthma, Chronic Obstructive Pulmonary Disease and Other Combinations. *Arch Bronconeumol*. 2016; 52(10): 499-500.

15. Golpe R, Mateos-Colino A, Testa-Fernández A, Pena-Seijo M, Rodríguez-Enríquez M, González-Juanatey C, Martín-Vázquez FJ, Pose-Reino A, Domínguez-Pin N, Garnacho-Gayarre N, Pérez-de-Llano LA. Blood Pressure Profile and Hypertensive Organ Damage in COPD Patients and Matched Controls. The RETAPOC Study. *PLoS One*. 2016; 11(6): e0157932.
16. Golpe R, Martín-Robles I, Sanjuán-López P, Cano-Jiménez E, Castro-Añon O, Mengual-Macén N, Pérez-de-Llano L. Prevalence of Major Comorbidities in Chronic Obstructive Pulmonary Disease Caused by Biomass Smoke or Tobacco. *Respiration*. 2017 Apr 29. doi: 10.1159/000472718.
17. Cosío BG, Pérez de Llano L, Lopez Viña A, Torrego A, Lopez-Campos JL, Soriano JB, Martinez Moragon E, Izquierdo JL, Bobolea I, Callejas J, Plaza V, Miravittles M, Soler-Catalunya JJ; on behalf of the CHACOS study group. Th-2 signature in chronic airway diseases: towards the extinction of asthma-COPD overlap syndrome? *Eur Respir J*. 2017 May 1;49(5). pii: 1602397.
18. Miravittles M, Alvarez-Gutierrez FJ, Calle M, Casanova C, Cosio BG, López-Viña A, Pérez de Llano L, Quirce S, Roman-Rodríguez M, Soler-Cataluña JJ, Plaza V. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. *Eur Respir J*. 2017 May 1;49(5). pii: 1700068.
19. Plaza V, Álvarez F, Calle M, Casanova C, Cosío BG, López-Viña A, Pérez de Llano L, Quirce S, Román-Rodríguez M, Soler-Cataluña JJ, Miravittles M. Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). *Arch Bronconeumol*. 2017 May 8. pii: S0300-2896(17)30092-3.
20. Palomares Ó, Sánchez-Ramón S, Dávila I, Prieto L, Pérez de Llano L, Leonart M, Domingo C, Nieto A. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. *Int J Mol Sci*. 2017 Jun 21;18(6). pii: E1328.
21. Nieto Cano S, Golpe Gómez R, Pérez de Llano LA. The Need for Palliative Care in Chronic Respiratory Patients With Non-Malignant Disease. *Arch Bronconeumol*. 2017 Sep 14. pii: S0300-2896(17)30275-2.

22. Golpe R, Martín-Robles I, Sanjuán-López P, Pérez-de-Llano L, González-Juanatey C, López-Campos JL, Arellano-Orden E. Differences in systemic inflammation between cigarette and biomass smoke-induced COPD. *Int J Chron Obstruct Pulmon Dis*; 12: 2639-2646.
23. Pérez-de-Llano L, Cosío BG; CHACOS study group. Asthma-COPD overlap is not a homogeneous disorder: further supporting data. *Respir Res*. 2017; 18(1): 183.
24. de Llano LP, Cosío BG, Iglesias A, de Las Cuevas N, Soler-Cataluña JJ, Izquierdo JL, López-Campos JL, Calero C, Plaza V, Miravittles M, Torrego A, Martínez-Moragon E, Soriano JB, Viña AL, Bobolea I. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach. *Int J Chron Obstruct Pulmon Dis*. 2018; 13: 591-601.
25. Pérez de Llano L, López-Campos JL, Cosío BG. The post-truth behind the asthma-COPD overlap and the orbit of Mercury: lessons from the CHACOS study. *Arch Bronconeumol* 2018; 54(4): 175-176.
26. Golpe R, Sanjuán-López P, Martín-Robles I, González-Juanatey C, Pérez-de-Llano L, López-Campos JL. Cardiovascular Studies in Patients with Chronic Obstructive Pulmonary Disease Due to Biomass Smoke or Tobacco. *Lung*. 2018; 196(2): 195-200.
27. Golpe R, Suárez-Valor M, Castro-Añón O, Pérez-de-Llano LA. Risk Stratification in Chronic Obstructive Pulmonary Disease. Can the Spanish Guidelines be Improved? *Arch Bronconeumol*. 2018. pii: S0300-2896(18)30050-4.
28. Golpe R, Suárez-Valor M, Martín-Robles I, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O, Pérez de Llano LA. Mortality in COPD patients according to clinical phenotypes. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 1433-1439.
29. Pérez de Llano L, Cosío BG, Miravittles M, Plaza V; CHACOS study group. Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease. *Arch Bronconeumol* 2018; 54(4): 198-204.
30. Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG, Peters M, Hew M, van Boven JFM, Lehtimäki L, van Ganse E, Belhassen M, Harvey ES, Perez de Llano L, Maitland-van der Zee AH, Papadopoulos NG, FitzGerald JM, Porsbjerg C, Canonica GW, Backer V, Rhee CK, Verhamme KMC, Buhl R, Cosío

- BG, Carter V, Price C, Le T, Stagno d'Alcontres M, Gopalan G, Tran TN, Price D. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. *J Allergy Clin Immunol Pract.* 2018 Sep 1. pii: S2213-2198(18)30552-X.
31. Cosío BG, Dacal D, Pérez de Llano L. Asthma-COPD overlap: identification and optimal treatment. *Ther Adv Respir Dis.* 2018 Jan-Dec; 12:1753466618805662.
  32. Pérez de Llano L, García-Rivero JL, Urrutia I, Martínez-Moragón E, Ramos J, Ce-bollero P, Carballada F, Blanco M, Vennera MDC, Merino M, García Nr YT, Plaza V. A simple score for future risk prediction in patients with controlled asthma who undergo a guidelines-based step-down strategy. *J Allergy Clin Immunol Pract.* 2018. pii: S2213-2198(18)30674-3.
  33. Golpe R, Suárez-Valor M, Veiga-Teijeiro I, Veres-Racamonde A, Pérez-de-Llano LA. Should Lung Function Be Included in the Risk Stratification of Chronic Obstructive Pulmonary Disease Proposed by GesEPOC? *Arch Bronconeumol.* 2019 Jan 11. pii: S0300-2896(18)30471-X. doi: 10.1016/j.arbres.2018.12.007.
  34. Pérez de Llano et al. Efficacy and safety of reslizumab in severe asthma patients with inadequate response to omalizumab: a multicentre, open-label, pilot study. *J Allergy Clin Immunol Pract.* 2019. In press.
  35. Pérez de Llano L, Martínez-Moragón E, Plaza Moral V, Trisan Alonso A, Sánchez CA, Callejas FJ, Vera E, Soto Campos JG, Martinez Rivera C, Alcázar Navarrete B, Urrutia Landa I, Garcia Rivero JL, Padilla Galo A, Alvarez Gutierrez F, Landete P, Ramos González J, Aracil CF, Carretero Gracia JÁ, Lluch I, Puente L, Andujar-Espinosa R, Cosío BG. Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. *Respir Med.* 2019; 151 :49-54.
  36. Pérez de Llano LA, Dacal Rivas D, Cosío BG. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. *Allergy.* 2020; 75(4): 940-942.
  37. Golpe R, Dacal D, Sanjuán-López P, Martín-Robles I, Pérez-de-Llano LA. Plasma Eosinophil Count and Patient-Centered Events in Chronic Obstructive Pulmonary Disease in Real-Life Clinical Practice. *Arch Bronconeumol.* 2020; 56(2): 129-130.

38. Pérez de Llano L, Rivas DD. Asthma Attacks and Cardiovascular Events: Earthquakes and Tsunamis. *J Allergy Clin Immunol Pract.* 2020; 8(1): 195-196.
39. Mokhlesi B, Masa JF, Afshar M, Almadana Pacheco V, Berlowitz DJ, Borel JC, Budweiser S, Carrillo A, Castro-Añón O, Ferrer M, Gagnadoux F, Golpe R, Hart N, Howard ME, Murphy PB, Palm A, Perez de Llano LA, Piper AJ, Pépin JL, Priou P, Sánchez-Gómez JF, Soghier I, Tamae Kakazu M, Wilson KC. The Effect of Hospital Discharge with Empiric Noninvasive Ventilation on Mortality in Hospitalized Patients with Obesity Hypoventilation Syndrome. An Individual Patient Data Meta-Analysis. *Ann Am Thorac Soc.* 2020; 17(5): 627-637.
40. Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Hernández-Martín I, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. *Allergy.* 2020; 75(5): 1023-1042.
41. Agache I, Song Y, Rocha C, Beltran J, Posso M, Steiner C, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthma. *Allergy.* 2020; 75(5): 1058-1068.
42. Agache I, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Del Giacco S, Eiwegger T, Flood B, Firinu D, Gern JE, Hamelmann E, Hanania N, Hernández-Martín I, Knibb R, Mäkelä M, Nair P, O Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Pfaar O, Quirce S, Sastre J, Shamji M, Schwarze J, Palomares O, Jutel M. EAACI Biologicals Guidelines - Recommendations for severe asthma. *Allergy.* 2021;76(1): 14-44. doi: 10.1111/all.14425.

43. Pérez de Llano LA, Quirce Gancedo S, Plaza Moral V. Treatment of Moderate-severe Asthma: An Alternative Strategy to the Guidelines Recommendations. *Arch Bronconeumol*. 2020 Jun 1: S0300-2896(20)30136-8.
44. Bhalla A, Zhao N, Rivas DD, Ho T, Perez de Llano L, Mukherjee M, Nair P. Exacerbations of severe asthma while on Anti-IL5 biologicals. *J Investig Allergol Clin Immunol*. 2020 Jun 23:0. doi: 10.18176/jiaci.0628.
45. Golpe R, Blanco N, Castro-Añón O, Corredoira J, García-Pais MJ, Pérez-de-Llano LA, Rabuñal R, Romay E, Suárez R; en representación del grupo COVID-19 de Lugo. Factors Associated to Hospital Admission in a Care Protocol in COVID-19. *Arch Bronconeumol*. 2020 Jun 17: S0300-2896(20)30196-4.
46. Golpe R, Pérez-de-Llano LA, Dacal D, Guerrero-Sande H, Pombo-Vide B, Ventura-Valcárcel P; Lugo Covid-19 team. Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors. *Med Clin (Barc)*. 2020 Jun 25:S0025-7753(20)30402-4.
47. Soriano JB, Fernandez E, de Astorza Á, Pérez de Llano LA, Fernández Villar JA, Carnicer-Pont D, et al. Hospital Epidemics Tracker (HEpiTracker): Description and pilot study of a mobile app to track COVID-19 in hospital workers. *JMIR Public Health Surveill*. 2020 Aug 21. doi: 10.2196/21653.
48. FitzGerald JM, Tran TN, Alacqua M, Altraja A, Backer V, Bjermer L, Bjornsdottir U, Bourdin A, Brusselle G, Bulathsinhala L, Busby J, Canonica GW, Carter V, Chaudhry I, Cho YS, Christoff G, Cosio BG, Costello RW, Eleangovan N, Gibson PG, Heaney LG, Heffler E, Hew M, Hosseini N, Iwanaga T, Jackson DJ, Jones R, Koh MS, Le T, Lehtimäki L, Ludviksdottir D, Maitland-van der Zee AH, Menzies-Gow A, Murray RB, Papadopoulos NG, Perez-de-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Price CA, Rhee CK, Sadatsafavi M, Tohda Y, Wang E, Wechsler ME, Zangrilli J, Price DB. International severe asthma registry (ISAR): protocol for a global registry. *BMC Med Res Methodol*. 2020 Aug 14;20(1):212.
49. Pérez de Llano L, Blanco Cid N, Martín Robles I, Golpe R, Castro-Añón O, Dacal Rivas D. Regarding the role of F ENO in predicting failure after ICS reduction in mild-to-moderate asthma patients. *Eur Respir J*. 2020 Aug 20;56(2):2002375.
50. FitzGerald JM, Tran TN, Alacqua M, Altraja A, Backer V, Bjermer L, Bjornsdottir U, Bourdin A, Brusselle G, Bulathsinhala L, Busby J, Canonica GW, Carter V,

- Chaudhry I, Cho YS, Christoff G, Cosio BG, Costello RW, Eleangovan N, Gibson PG, Heaney LG, Heffler E, Hew M, Hosseini N, Iwanaga T, Jackson DJ, Jones R, Koh MS, Le T, Lehtimäki L, Ludviksdottir D, Maitland-van der Zee AH, Menzies-Gow A, Murray RB, Papadopoulos NG, Perez-de-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Price CA, Rhee CK, Sadatsafavi M, Tohda Y, Wang E, Wechsler ME, Zangrilli J, Price DB. International severe asthma registry (ISAR): protocol for a global registry. *BMC Med Res Methodol*. 2020; 20(1): 212.
51. Pérez de Llano L, Miravittles M, Golpe R, Alvarez-Gutiérrez FJ, Cisneros C, Almonacid C, Martínez-Moragón E, González-Barcala FJ, Ramos-Barbón D, Plaza V, López-Campos JL, de-Torres JP, Casanova C, García Rivero JL, Rodríguez Hermosa J, Calle Rubio M, Soler-Cataluña JJ, Cosio BG. A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future. *Int J Chron Obstruct Pulmon Dis*. 2020; 15: 2091-2100.
52. Pérez de Llano L, Blanco Cid N, Ortiz Piquer M, Dacal Rivas D. Compassionate Use of a Single Dose of Benralizumab in a Near-Fatal Asthma Exacerbation. *J Investig Allergol Clin Immunol*. 2020 Sep 15:0. doi: 10.18176/jiaci.0609.
53. Crespo-Lessmann A, Plaza V; Consensus Group, Almonacid C, Caballero Soto ML, Cañas JA, Carretero Gracia JÁ, Cruz MJ, Dacal Rivas D, Del Camino Muñiz M, Pérez Del Llano L, Del Pozo V, López Carrasco V, Marín Trigo JM, Mateus E, Muñoz X, Olaguíbel JM, Quirce S, Ramos D, Sanz Rubio D, Sastre J, Vázquez Martín S, Vera Solsona E. Multidisciplinary consensus on sputum induction biosafety during the COVID-19 pandemic. *Allergy*. 2020 Dec 12. doi: 10.1111/all.14697.
54. Pérez de Llano L, Dacal-Rivas D, Blanco-Cid N, Martín-Robles I. Distilling fact from the vapor of nuance: asthma exacerbations. *J Allergy Clin Immunol Pract*. 2021; 9(2): 842-843. doi: 10.1016/j.jaip.2020.10.007.
55. Pérez de Llano L, Dávila I, Martínez-Moragón E, Domínguez-Ortega J, Almonacid C, Colás C, García-Rivero JL, Carmona L, García de Yébenes MJ, Cosío BG; FEOS Study Group. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score. *J Allergy Clin Immunol Pract* 2021: S2213-2198(21)00161-6. doi: 10.1016/j.jaip.2021.01.033.

56. Almonacid C, Melero C, López Viña A, Cisneros C, Pérez de Llano L, Plaza V, García-Rivero JL, Romero Falcón A, Ramos J, Bazús González T, Andrés Prado M, Muriel A. Effectiveness of Text Message Reminders on Adherence to Inhaled Therapy in Patients With Asthma: Prospective Multicenter Randomized Clinical Trial. *JMIR Form Res.* 2021; 5(2): e12218. doi: 10.2196/12218.
57. Pérez de Llano, L, Dacal Rivas D, Blanco Cid, N, Martin Robles I. Phenotype-guided asthma therapy: an alternative approach to guidelines. *J Asthma Allergy* 2021. In press. *J Asthma Allergy.* 2021; 14:207-217. doi: 10.2147/JAA.S266999.
58. Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, Sadatsafavi M, Perez de Llano L, Christoff G, Quinton A, Rhee CK, Brusselle G, Ulrik C, Lugogo N, Hore-Lacy F, Chaudhry I, Bulathsinhala L, Murray RB, Carter VA, Hew M. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry (ISAR). *J Allergy Clin Immunol Pract.* 2021: S2213-2198(21)00311-1. doi: 10.1016/j.jaip.2021.02.059.
59. Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, Christoff GC, Cosio BG, FitzGerald JM, Heffler E, Iwanaga T, Jackson DJ, Menzies-Gow AN, Papadopoulos NG, Papaioannou AI, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sadatsafavi M, Tohda Y, Wang E, Wechsler ME, Alacqua M, Altraja A, Bjermer L, Björnsdóttir US, Bourdin A, Brusselle GG, Buhl R, Costello RW, Hew M, Siyue MK, Lehmann S, Lehtimäki L, Peters M, Taillé C, Taube C, Tran TN, Zangrilli J, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Hosseini N, Kerkhof M, Murray RB, Price CA, Price DB. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. *Chest.* 2021: S0012-3692(21)00700-5. doi: 10.1016/j.chest.2021.04.013.
60. de Llano LAP, Golpe R, Pérez-Ortiz D, Menéndez R, Yandiola PPE, Artaraz A, Zalacain R, Cilloniz C, Torres A. Early initiation of corticosteroids might be harmful in patients hospitalized with COVID-19 pneumonia: A multicenter propensity score analysis. *Arch Bronconeumol.* 2021. doi: 10.1016/j.arbres.2021.10.001.
61. de Llano LP, Naval E, Mejía N, Domínguez-Ortega J. Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma. *Expert Rev Respir Med.* 2022; 16(1): 1-15.

62. Pérez-de-Llano L, Romay-Lema EM, Baloira-Villar A, Anchorena C, Torres-Durán ML, Sousa A, Corbacho-Abelaira D, Paz-Ferrin J, Diego-Roza C, Vilariño-Maneiro L, Marcos PJ, Montero-Martínez C, de la Iglesia-Martínez F, Riveiro-Blanco V, Rodríguez-Núñez N, Abal-Arca J, Bustillo-Casado M, Golpe R. COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation. *PLoS One*. 2021 Jun 23;16(6):e0253465.
63. Kerkhof M, Tran TN, Allehebi R, Canonica GW, Heaney LG, Hew M, Perez de Llano L, Wechsler ME, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Murray RB, Price CA, Price DB. Asthma Phenotyping in Primary Care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm Across All Asthma Severities. *J Allergy Clin Immunol Pract*. 2021; 9(12): 4353-4370.
64. Rodríguez-García C, Blanco-Aparicio M, Nieto-Fontarigo JJ, Blanco-Cid N, Gonzalez-Fernandez C, Mosteiro-Añon M, Calvo-Alvarez U, Perez-De-Llano L, Corbacho-Abelaira MD, Lourido-Cebreiro T, Dominguez-Juncal LM, Crespo-Diz C, Dacal-Quintas R, Pallares-Sanmartin A, Dacal-Rivas D, Gonzalez-Barcala FJ. Efficacy of mepolizumab in usual clinical practice and characteristics of responders. *Respir Med*. 2021; 187: 106595.
65. Agache I, Antolin-Amerigo D, de Blay F, Boccabella C, Caruso C, Chanez P, Couto M, Covar R, Doan S, Fauquert JL, Gauvreau G, Gherasim A, Klimek L, Lemiere C, Nair P, Ojanguren I, Peden D, Perez-de-Llano L, Pfaar O, Rondon C, Rukhazde M, Sastre J, Schulze J, Silva D, Tarlo S, Toppila-Salmi S, Walusiak-Skorupa J, Zielen S, Eguiluz-Gracia I. EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. *Allergy*. 2022 Jan 2. doi: 10.1111/all.15203.
66. Porsbjerg CM, Menzies-Gow AN, Tran TN, Murray RB, Unni B, Audrey Ang SL, Alacqua M, Al-Ahmad M, Al-Lehebi R, Altraja A, Belevskiy AS, Björnsdóttir US, Bourdin A, Busby J, Canonica GW, Christoff GC, Cosio BG, Costello RW, FitzGerald JM, Fonseca JA, Hansen S, Heaney LG, Heffler E, Hew M, Iwanaga T, Jackson DJ, Kocks JWH, Kallieri M, Bruce Ko HK, Koh MS, Larenas-Linnemann D, Lehtimäki LA, Loukides S, Lugogo N, Maspero J, Papaioannou AI, Perez-de-Llano

- L, Pitrez PM, Popov TA, Rasmussen LM, Rhee CK, Sadatsafavi M, Schmid J, Siddiqui S, Taillé C, Taube C, Torres-Duque CA, Ulrik C, Upham JW, Wang E, Wechsler ME, Bulathsinhala L, Carter V, Chaudhry I, Eleangovan N, Hosseini N, Rowlands MA, Price D, van Boven JF. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. *J Allergy Clin Immunol Pract.* 2022: S2213-2198(21)01454-9.
67. Menzies-Gow AN, McBrien C, Unni B, Porsbjerg CM, Al-Ahmad M, Ambrose CS, Dahl Assing K, von Bülow A, Busby J, Cosio BG, FitzGerald JM, Garcia Gil E, Hansen S, aHeaney LG, Hew M, Jackson DJ, Kallieri M, Loukides S, Lugogo NL, Papaioannou AI, Larenas-Linnemann D, Moore WC, Perez-de-Llano LA, Rasmussen LM, Schmid JM, Siddiqui S, Alacqua M, Tran TN, Suppli Ulrik C, Upham JW, Wang E, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Murray RB, Price CA, Price DB. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. *J Asthma Allergy.* 2022; 15: 63-78.
68. Pérez de Llano LA, Cosío BG, Lobato Astiárraga I, Soto Campos G, Tejedor Alonso MÁ, Marina Malanda N, Padilla Galo A, Urrutia Landa I, Michel de la Rosa FJ, García-Moguel I; Reslizumab Real-Life Spanish Group. Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data. *J Asthma Allergy.* 2022; 15: 79-88.
69. Pérez de Llano L, Dacal Rivas D, Marina Malanda N, Plaza Moral V, Gullón Blanco JA, Muñoz-Esquerre M, García-Moguel I, Díaz Campos RM, Martínez-Moragón E, Harbenau Mena A, Cosío BG, Padilla Galo A, Cisneros Serrano C. The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome *J Asthma Allergy.* 2022; 15: 363-369.
70. Chiner-Vives E, Cordovilla-Pérez R, de la Rosa-Carrillo D, García-Clemente M, Izquierdo-Alonso JL, Otero-Candelera R, Pérez-de Llano L, Sellares-Torres J, de Granda-Orive JI. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. *Arch Bronconeumol.* 2022;
71. Menéndez R, Méndez R, González-Jiménez P, Zalacain R, Ruiz LA, Serrano L, España PP, Uranga A, Cillóniz C, Pérez-de-Llano L, Golpe R, Torres A. Early Recog-

- nition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria. *Chest*. 2022; 162(4): 768-781.
72. Pérez de Llano LA, Cosío BG, Lobato Astiárraga I, Soto Campos G, Tejedor Alonso MA, Malanda NM, Padilla Galo A, Urrutia Landa I, Michel de la Rosa FJ, García-Moguel I; Reslizumab real-life Spanish group. First line versus second line use of reslizumab in severe uncontrolled asthma. *J Investig Allergol Clin Immunol*. 2022 Jun 27:0. doi: 10.18176/jiaci.0839.
73. Pérez de Llano L, Cisneros C, Domínguez-Ortega J, Martínez-Moragón E, Olaguibel JM, Plaza V, Quirce S, Dávila I. Response to monoclonal antibodies in asthma: definitions, potential reasons for failure and therapeutic options for suboptimal response. *J Investig Allergol Clin Immunol*. 2022 Aug 30:0. doi: 10.18176/jiaci.0857.
74. de Llano LP, Naval E, Mejía N, Domínguez-Ortega J. Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma. *Expert Rev Respir Med*. 2022;16 (1): 1-15.
75. Canonica GW, Spanevello A, de Llano LP, Domingo Ribas C, Blakey JD, Garcia G, Inoue H, Dalcolmo M, Yang D, Mokashi S, Kurne A, Butta AK. Is asthma control more than just an absence of symptoms? An expert consensus statement. *Respir Med*. 2022; 202: 106942. doi: 10.1016/j.rmed.2022.106942.
76. Chen W, Sadatsafavi M, Tran TN, Murray RB, Wong CBN, Ali N, Ariti C, Garcia Gil E, Newell A, Alacqua M, Al-Ahmad M, Altraja A, Al-Lehebi R, Bhutani M, Bjerrum L, Bjerrum AS, Bourdin A, Bulathsinhala L, von Bülow A, Busby J, Canonica GW, Carter V, Christoff GC, Cosio BG, Costello RW, FitzGerald JM, Fonseca JA, Yoo KH, Heaney LG, Heffler E, Hew M, Hilberg O, Hoyte F, Iwanaga T, Jackson DJ, Jones RC, Koh MS, Kuna P, Larenas-Linnemann D, Lehmann S, Lehtimäki LA, Lyu J, Mahboub B, Maspero J, Menzies-Gow AN, Sirena C, Papadopoulos N, Papaioannou AI, Pérez de Llano L, Perng DW, Peters M, Pfeffer PE, Porsbjerg CM, Popov TA, Rhee CK, Salvi S, Taillé C, Taube C, Torres-Duque CA, Ulrik CS, Ra SW, Wang E, Wechsler ME, Price DB. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not

- Initiate Biologic Therapy. *J Asthma Allergy*. 2022; 15:1491-1510. doi: 10.2147/JAA.S377174.
77. Golpe R, Blanco-Cid N, Dacal-Rivas D, Martín-Robles I, Veiga I, Guzmán-Peralta I, Castro-Añón O, Pérez-de-Llano LA. Incidence and profile of severe exacerbations of chronic obstructive pulmonary disease due to biomass smoke or tobacco. *Ann Thorac Med*. 2022: 193-198. doi: 10.4103/atm.atm\_155\_22.
78. Pérez de Llano L, Martínez Moragón E, Entrenas LM, Martínez Rivera C, Cisneros C, Blanco-Aparicio M, Trisán A, Plaza V, Ramos J, Funenga Fitas E, Sanchez-Covisa J, Dominguez-Ortega J. Validation of the Asthma Impairment and Risk Questionnaire (AIRQ) in Spain: a useful tool to assess asthma control in adolescent and adult patients. *J Investig Allergol Clin Immunol*. 2022 Dec 15:0. doi: 10.18176/jiaci.0881.
79. Golpe R, Figueira-Gonçalves JM, Dacal-Rivas D, Blanco-Cid N, Guzmán-Peralta I, Castro-Añón O, Pérez-de-Llano LA. Nocturnal Dyspnea During Severe Exacerbations Is Associated With Mortality Risk in COPD. *Respir Care*. 2023 Mar;68(3):413-416. doi: 10.4187/respcare.10310.
80. Pérez de Llano L, Marina Malanda N, Urrutia I, Martínez-Moragón E, Gullón-Blanco JA, Díaz-Campos R, Esquerre MM, Alicia HM, Cosío BG, Cisneros C, Polo FJL, Laorden D, Dacal Rivas D. Factors associated with suboptimal response to monoclonal antibodies in severe asthma. *Allergy*. 2023 Mar 3. doi: 10.1111/all.15693.
81. Cosío BG, Shafiek H, Mosteiro M, Iglesias A, Gómez C, Toledo-Pons N, Martinez R, Lopez M, Gimeno IE, Pérez de Llano L. Redefining the Role of Bronchoscopy in the Workup of Severe Uncontrolled Asthma in the Era of Biologics: A Prospective Study. *Chest*. 2023: S0012-3692(23)00354-9. doi: 10.1016/j.chest.2023.03.012.
82. Pfeffer PE, Ali N, Murray R, Ulrik C, Tran TN, Maspero J, Peters M, Christoff GC, Sadatsafavi M, Torres-Duque CA, Altraja A, Lehtimäki L, Papadopoulos NG, Salvi S, Costello RW, Cushen B, Heffler E, Iwanaga T, Al-Ahmad M, Larenas-Linne-mann D, Kuna P, Fonseca JA, Al-Lehebi R, Rhee CK, Perez-de-Llano L, Perng Steve DW, Mahboub B, Wang E, Goh C, Lyu J, Newell A, Alacqua M, Belevskiy AS, Bhutani M, Bjermer L, Bjornsdottir U, Bourdin A, Bulow AV, Busby J, Canon-

- ica GW, Cosio BG, Dorscheid DR, Muñoz-Esquerre M, FitzGerald JM, Gil EG, Gibson PG, Heaney LG, Hew M, Hilberg O, Hoyte F, Jackson DJ, Koh MS, Ko HB, Lee JH, Lehmann S, Chaves Loureiro C, Lúðvíksdóttir D, Menzies-Gow AN, Mitchell P, Papaioannou AI, Popov TA, Porsbjerg CM, Salameh L, Sirena C, Taillé C, Taube C, Tohda Y, Wechsler ME, Price DB. Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both. *Allergy*. 2023. doi: 10.1111/all.15711.
83. Pérez-de-Llano L, Veiga-Teijeiro I, Dacal-Rivas D. Contribution of the Remission Concept to the Treatment of Asthma. *Arch Bronconeumol*. 2023: S0300-2896(23)00108-4. doi: 10.1016/j.arbres.2023.03.009.
84. Kroes JA, Alfonso-Cristancho R, Bansal AT, Berret E, Bieksiene K, Bourdin A, Brussino L, Canhoto D, Cardini C, Celik G, Csoma Z, Dahlén B, Damadoglu E, Eger K, Gauquelin L, Gemicioglu B, Goksel O, Graff S, Heffler E, Hofstee HB, Howarth P, Jakes RW, Jaun F, Kalinauskaite-Zukauske V, Kopač P, Kwon N, Loureiro CC, Lozoya García V, Masoli M, Rezelj MP, Pérez De Llano L, Popović-Grle S, Ramos-Barbón D, Sà Sousa A, Samitas K, Schleich F, Sirena C, Skrgat S, Zervas E, Zichnalis G, Bel EH, Sont JK, Hashimoto S, Ten Brinke A. Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis. *ERJ Open Res*. 2023; 9(2): 00745-2022. doi: 10.1183/23120541.00745-2022.
85. Chen W, Tran TN, Sadatsafavi M, Murray R, Wong NCB, Ali N, Ariti C, Bulathsinhala L, Gil EG, FitzGerald JM, Alacqua M, Al-Ahmad M, Altraja A, Al-Lehebi R, Bhutani M, Bjermer L, Bjerrum AS, Bourdin A, von Bülow A, Busby J, Walter Canonica G, Carter V, Christoff GC, Cosio BG, Costello RW, Fonseca JA, Gibson PG, Yoo KH, Heaney LG, Heffler E, Hew M, Hilberg O, Hoyte F, Iwanaga T, Jackson DJ, Jones RC, Koh MS, Kuna P, Larenas-Linnemann D, Lehmann S, Lehtimäki L, Lyu J, Mahboub B, Maspero J, Menzies-Gow AN, Newell A, Sirena C, Papadopoulos NG, Papaioannou AI, Perez-de-Llano L, Perng Steve DW, Peters M, Pfeffer PE, Porsbjerg CM, Popov TA, Rhee CK, Salvi S, Taillé C, Taube C, Torres-Duque CA, Ulrik C, Ra SW, Wang E, Wechsler ME, Price DB. Impact of initiating biologics in patients with severe asthma on long-term OCS or frequent rescue steroids (GLITTER): data from the International Severe Asthma Registry. *J All*

- lery Clin Immunol Pract. 2023: S2213-2198(23)00643-8. doi: 10.1016/j.jaip.2023.05.044.
86. Almonacid-Sánchez C, García-Cosío B, Trisán-Alonso A, Callejas-González FJ, Cisneros C, Martínez-Moragón E, Plaza Moral V, Vera E, Soto-Campos JG, Martínez-Rivera C, Alcazar-Navarrete B, Urrutia Landa I, García-Rivero JL, Padilla Galo A, Álvarez-Gutierrez F, Ramos-González J, Carretero-Gracia JÁ, Lluch I, Puente L, Andujar-Espinosa R, Pérez-de-Llano L. Therapeutic Goals and Treatable Traits: Long-Term Trends in a Severe Asthma Population. *Arch Bronconeumol.* 2023 Oct 5:S0300-2896(23)00310-1. doi: 10.1016/j.arbres.2023.08.017.
87. Pérez de Llano L, Muñiz Fernández MC, Dávila I. Impact of the ERS/ATS 2021 guidelines for lung function interpretation on assessing the response to biologics in asthma. *J Investig Allergol Clin Immunol.* 2023 Sep 18:0. doi: 10.18176/jiaci.0943.
88. Canonica GW, Spanevello A, de Llano LP, Ribas CD, Blakey JD, Garcia G, Inoue H, Dalcolmo M, Yang D, Mokashi S, Kurne A, Butta AK. Asthma control conundrum in clinical practice - Data from a two-stage Delphi survey and literature review. *Data Brief.* 2023 Jul 18; 50:109422. doi: 10.1016/j.dib.2023.109422.
89. Scelo G, Torres-Duque CA, Maspero J, Tran TN, Murray R, Martin N, Menzies-Gow AN, Hew M, Peters MJ, Gibson PG, Christoff GC, Popov TA, Côté A, Bergeron C, Dorscheid D, FitzGerald JM, Chapman KR, Boulet LP, Bhutani M, Sadatsafavi M, Jiménez-Maldonado L, Duran-Silva M, Rodriguez B, Celis-Preciado CA, Cano-Rosales DJ, Solarte I, Fernandez-Sanchez MJ, Parada-Tovar P, von Bülow A, Bjerrum AS, Ulrik CS, Assing KD, Rasmussen LM, Hansen S, Altraja A, Bourdin A, Taille C, Charriot J, Roche N, Papaioannou AI, Kostikas K, Papadopoulos NG, Salvi S, Long D, Mitchell PD, Costello R, Sirena C, Cardini C, Heffler E, Puggioni F, Canonica GW, Guida G, Iwanaga T, Al-Ahmad M, Linnemann DL, Garcia U, Kuna P, Fonseca JA, Al-Lehebi R, Koh MS, Rhee CK, Cosio BG, de Llano LP, Perng Steve DW, Huang EW, Wang HC, Tsai MJ, Mahboub B, Salameh LIJ, Jackson D, Busby J, Heaney LG, Pfeffer P, Goddard AG, Wang E, Hoyte F, Wechsler ME, Chapman N, Katial R, Carter V, Bulathsinhala L, Eleangovan N, Ariti C, Lyu J, Price DB, Porsbjerg C. Analysis of comorbidities and multimorbidity in adult patients in the In-

- ternational Severe Asthma Registry. *Ann Allergy Asthma Immunol.* 2023 Aug 26:S1081-1206(23)00630-0. doi: 10.1016/j.anai.2023.08.021.
90. Wechsler ME, Scelo G, Larenas-Linnemann DES, Torres-Duque CA, Maspero J, Tran TN, Murray RB, Martin N, Menzies-Gow AN, Hew M, Peters MJ, Gibson PG, Christoff GC, Popov TA, Côté A, Bergeron C, Dorscheid D, FitzGerald JM, Chapman KR, Boulet LP, Bhutani M, Sadatsafavi M, Jiménez-Maldonado L, Duran-Silva M, Rodriguez B, Celis-Preciado CA, Cano-Rosales DJ, Solarte I, Fernandez-Sanchez MJ, Parada-Tovar P, von Bülow A, Bjerrum AS, Ulrik CS, Assing KD, Rasmussen LM, Hansen S, Altraja A, Bourdin A, Taille C, Charriot J, Roche N, Papaioannou AI, Kostikas K, Papadopoulos NG, Salvi S, Long D, Mitchell PD, Costello R, Sirena C, Cardini C, Heffler E, Puggioni F, Canonica GW, Guida G, Iwanaga T, Al-Ahmad M, García U, Kuna P, Fonseca JA, Al-Lehebi R, Koh MS, Rhee CK, Cosio BG, Perez de Llano L, Perng DW, Huang EW, Wang HC, Tsai MJ, Mahboub B, Salameh LIJ, Jackson DJ, Busby J, Heaney LG, Pfeffer PE, Goddard AG, Wang E, Hoyte FCL, Chapman NM, Katial R, Carter V, Bulathsinhala L, Elean-govan N, Ariti C, Lyu J, Porsbjerg C, Price DB. Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma. *Am J Respir Crit Care Med.* 2023. doi: 10.1164/rccm.202305-0808OC.
91. Perez-de-Llano L, Scelo G, Canonica GW, Chen W, Henley W, Larenas-Lin-nemann D, Peters MJ, Pfeffer PE, Tran TN, Ulrik CS, Popov TA, Sadatsafavi M, Hew M, Maspero J, Gibson PG, Christoff GC, FitzGerald JM, Torres-Duque CA, Porsb-erg CM, Papadopoulos NG, Papaioannou AI, Heffler E, Iwanaga T, Al-Ahmad M, Kuna P, Fonseca JA, Al-Lehebi R, Rhee CK, Koh MS, Cosio BG, Perng Steve DW, Mahboub B, Menzies-Gow AN, Jackson DJ, Busby J, Heaney LG, Patel PH, Wang E, Wechsler ME, Altraja A, Lehtimäki L, Bourdin A, Bjermer L, Bulathsinhala L, Carter V, Murray R, Beastall A, Denton E, Price DB. Impact of pre-biologic im-pairment on meeting domain-specific biologic responder definitions in patients with severe asthma. *Ann Allergy Asthma Immunol.* 2023: S1081-1206(23)01508-9.
92. Pérez de Llano L, Urrutia I, G Cosío B, Gullón-Blanco JA, Habernau Mena A, Cis-neros C, Martínez-Moragón E, Marina Malanda N, Muñoz Esquerre M, Quirce S,

- Dacal Rivas D. Impact of comorbidities on the achievement of specific therapeutic goals in biologic-treated asthma patients. *Allergy*. 2024 Jan 5.
93. Palones E, García-Rivero JL, Cisneros C, Almonacid-Sánchez C, Pérez-de Llano L, Plaza V, Crespo-Lessmann A; Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Asthma Integrated Research Programme (PII) participants. Methodology Employed to Develop the Airway Mucus Secretion Test (T-SEC): A Questionnaire to Evaluate Airway Mucus Hypersecretion in Patients With Asthma. *Arch Bronconeumol*. 2024; 60(3):186-190. doi: 10.1016/j.arbres.2024.01.002.
94. Lee TY, Price D, Yadav CP, Roy R, Huey Mien LL, Wang E, Wechsler ME, Jackson DJ, Busby J, Heaney LG, Pfeffer PE, Mahboub B, Perng Steve DW, Cosio BG, Perez-de-Llano L, Al-Lehebi R, Larenas-Linnemann D, Al-Ahmad M, Rhee CK, Iwanaga T, Heffler E, Canonica GW, Costello R, Papadopoulos NG, Papaioannou AI, Porsbjerg CM, Torres-Duque CA, Christoff GC, Popov TA, Hew M, Peters M, Gibson PG, Maspero J, Bergeron C, Cerda S, Contreras Contreras EA, Chen W, Sadatsafavi M. International Variation in Severe Exacerbation Rates in Patients With Severe Asthma. *Chest*. 2024: S0012-3692(24)00264-2. doi: 10.1016/j.chest.2024.02.029.
95. Perez-de-Llano L, Scelo G, Tran TN, Le TT, Fagerås M, Cosio BG, Peters M, Pfeffer PE, Al-Ahmad M, Al-Lehebi RO, Altraja A, Bergeron C, Bjermer LH, Bjerrum AS, Bulathsinhala L, Busby J, Cano Rosales DJ, Canonica GW, Carter VA, Charriot J, Christoff GC, Denton EJ, Dorscheid DR, Fernandez Sanchez MJ, Fonseca JA, Gibson PG, Goh CYY, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann DES, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Popov TA, Porsbjerg CM, Patel P, Rhee CK, Sadatsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Severe Asthma Clinical Remission Post-Biologic in Adults. *Am J Respir Crit Care Med*. 2024. doi: 10.1164/rccm.202311-2192OC.
96. Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M,

Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Ławkiedraj A, Lehtimäki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodríguez-Cáceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, Máspero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taillé C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jiménez-Maldonado L, Taube C, Brussino L, Price DB. Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. *Front Immunol.* 2024 Apr 19; 15: 1361891. doi: 10.3389/fimmu.2024.1361891.

97. Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, Al-Ahmad M, Al-Lehebi R, Altraja A, Beastall A, Bergeron C, Bjermer L, Bjerrum AS, Cano-Rosales DJ, Canonica GW, Carter V, Charriot J, Christoff GC, Cosio BG, Denton E, Fernandez-Sanchez MJ, Fonseca JA, Gibson PG, Goh C, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann D, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Patel P, Perez-De-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sاداتsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Exploring Definitions and Predictors of Response to Biologics for Severe Asthma. *J Allergy Clin Immunol Pract.* 2024 May 19:S2213-2198(24)00530-0. doi: 10.1016/j.jaip.2024.05.016.

98. Menéndez R, Méndez R, González-Jiménez P, Latorre A, Reyes S, Zalacain R, Ruiz LA, Serrano L, España PP, Uranga A, Cillóniz C, Gaetano-Gil A, Fernández-Félix BM, Pérez-de-Llano L, Golpe R, Torres A. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia. *Sci Rep.* 2024 Jun 3;14(1):12726. doi: 10.1038/s41598-024-62718-4.

**Lugo a 22 de junio del 2024**

A handwritten signature in black ink on a light gray background. The signature is stylized and appears to be a name, possibly starting with 'M' or 'W', followed by several overlapping strokes that form a complex, cursive-like structure. The signature is positioned in the upper left quadrant of the page.